Alexander J. Bridges

8.4k citations

62 papers · 7.1k indexed · 3 hit papers · h-index 27

Co-authors: Alan R. Saltiel David T. Dudley Stuart J. Decker Long Pang David W. Fry Wilbur R. Leopold Amy McMichael James M. Nelson
Topics: HER2/EGFR in Cancer Research (16 papers)Quinazolinone synthesis and applications (11 papers)Synthesis and Characterization of Heterocyclic Compounds (9 papers)
Cited by: Oncology Organic Chemistry Molecular Biology
Journals: Science Chemical Reviews Proceedings of the National Academy of Sciences
Partner nations: United States New Zealand Japan

In The Last Decade

Alexander J. Bridges

61 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A synthetic inhibitor of the mitogen-activated protein kinase cascade.

1995 2.5k citations David T. Dudley, Long Pang et al. Proceedings of the National Academy of Sciences profile →
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1999 804 citations Judith S. Sebolt–Leopold, David T. Dudley et al. Nature Medicine profile →
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

1994 684 citations David W. Fry, Alan J. Kraker et al. profile →

Peers

Countries citing papers authored by Alexander J. Bridges

Since Specialization

Citations

This map shows the geographic impact of Alexander J. Bridges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander J. Bridges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander J. Bridges more than expected).

Fields of papers citing papers by Alexander J. Bridges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander J. Bridges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander J. Bridges. The network helps show where Alexander J. Bridges may publish in the future.

Co-authorship network of co-authors of Alexander J. Bridges

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander J. Bridges. A scholar is included among the top collaborators of Alexander J. Bridges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander J. Bridges. Alexander J. Bridges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics 2023 ·ACS Chemical Biology ·(unknown),Sarvind Tripathi,B. Gayani K. Perera,Dustin J. Maly,Alexander J. Bridges,Gert Kiss,Seth M. Rubin	8
2	Disruptin, a cell-penetrating peptide degrader of EGFR 2021 ·Translational Oncology ·Ranjit K. Mehta,(unknown),Susmita G. Ramanand,(unknown),Alexander J. Bridges,Theodore S. Lawrence,Mukesh K. Nyati	5
3	The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 2008 ·Bioorganic & Medicinal Chemistry Letters ·Stephen D. Barrett,Alexander J. Bridges,David T. Dudley,Alan R. Saltiel,James H. Fergus,Cathlin Flamme,Amy M. Delaney,Michael D. Kaufman,S Lepage,Wilbur R. Leopold,Sally Przybranowski,Judith S. Sebolt–Leopold,Keri Van Becelaere,Annette M. Doherty,Robert M. Kennedy,(unknown),(unknown),(unknown),Joseph S. Warmus,Haile Tecle	222
4	2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase) 2008 ·Bioorganic & Medicinal Chemistry Letters ·Joseph S. Warmus,Cathlin Flamme,(unknown),Stephen D. Barrett,Alexander J. Bridges,Huifen Chen,Richard Gowan,Michael D. Kaufman,(unknown),Wilbur R. Leopold,Ronald L. Merriman,Jeffrey F. Ohren,A.G. Pavlovsky,Sally Przybranowski,Haile Tecle,(unknown),Christopher E. Whitehead,Erli Zhang	60
5	Synthesis and structure–activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases 2007 ·European Journal of Medicinal Chemistry ·Jeff B. Smaill,Edward N. Baker,R J Booth,Alexander J. Bridges,James M. Dickson,Ellen M. Dobrusin,Ivan Ivanović,Alan J. Kraker,Ho H. Lee,Elizabeth A. Lunney,Daniel F. Ortwine,Brian D. Palmer,John Quin,C.J. Squire,Andrew M. Thompson,William A. Denny	28
6	Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. 2004 ·Cancer Research ·Michael D. Kaufman,Stephen D. Barrett,Cathlin Flamme,Joseph S. Warmus,(unknown),(unknown),(unknown),Haile Tecle,Judith S. Sebolt–Leopold,(unknown),Richard Gowan,Keri Van Becelaere,Ronald L. Merriman,Sally Przybranowski,Jeffrey F. Ohren,Christopher E. Whitehead,Wilbur R. Leopold,Ellen M. Dobrusin,Alexander J. Bridges	1
7	Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. 2000 ·Journal of Medicinal Chemistry ·Jeff B. Smaill,Gordon W. Rewcastle,Alexander J. Bridges,Hairong Zhou,H. D. Hollis Showalter,David W. Fry,James M. Nelson,(unknown),William L. Elliott,Patrick W. Vincent,(unknown),Joseph A. Loo,Kenneth D. Greis,O. Helen Chan,Eric L. Reyner,Elke Lipka,William A. Denny	12
8	Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivobreakdown → 1999 ·Nature Medicine ·Judith S. Sebolt–Leopold,David T. Dudley,Román Herrera,Keri Van Becelaere,(unknown),Richard Gowan,Haile Tecle,Stephen D. Barrett,Alexander J. Bridges,Sally Przybranowski,Wilbur R. Leopold,Alan R. Saltiel	804
9	Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor 1998 ·Proceedings of the National Academy of Sciences ·David W. Fry,Alexander J. Bridges,William A. Denny,Annette M. Doherty,Kenneth D. Greis,James L. Hicks,Kenneth E. Hook,Paul R. Keller,Wilbur R. Leopold,Joseph A. Loo,Dennis J. McNamara,James M. Nelson,(unknown),Jeff B. Smaill,Susanne Trumpp-Kallmeyer,Ellen M. Dobrusin	344
10	STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO 1996 ·Clinical and Experimental Pharmacology and Physiology ·William A. Denny,Gordon W. Rewcastle,Alexander J. Bridges,David W. Fry,Alan J. Kraker	23
11	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. 1995 ·Journal of Medicinal Chemistry ·Gordon W. Rewcastle,William A. Denny,Alexander J. Bridges,Hairong Zhou,(unknown),Amy McMichael,David W. Fry	223
12	A synthetic inhibitor of the mitogen-activated protein kinase cascade.breakdown → 1995 ·Proceedings of the National Academy of Sciences ·David T. Dudley,Long Pang,Stuart J. Decker,Alexander J. Bridges,Alan R. Saltiel	2522
13	Inhibitors of protein tyrosine kinases 1995 ·Current Opinion in Biotechnology ·David W. Fry,Alexander J. Bridges	21
14	The synthesis of three 4-substitutedbenzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase 1993 ·Bioorganic & Medicinal Chemistry ·Alexander J. Bridges,Arthur Lee,C. Schwartz,Murray J. Towle,Bruce A. Littlefield	22
15	New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk 1992 ·Journal of Medicinal Chemistry ·Joseph P. Sanchez,Alexander J. Bridges,(unknown),J. M. DOMAGALA,Rocco D. Gogliotti,Susan E. Hagen,Carl L. Heifetz,(unknown),(unknown)	20
16	N6-Bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor 1989 ·Journal of Medicinal Chemistry ·Bharat K. Trivedi,Alexander J. Bridges,William C. Patt,(unknown),Robert F. Bruns	42
17	N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor 1988 ·Journal of Medicinal Chemistry ·Alexander J. Bridges,Robert F. Bruns,Daniel F. Ortwine,(unknown),(unknown),Bharat K. Trivedi	64
18	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity 1987 ·Journal of Medicinal Chemistry ·Alexander J. Bridges,Walter H. Moos,(unknown),Bharat K. Trivedi,James A. Bristol,Thomas G. Heffner,Robert F. Bruns,David A. Downs	39
19	An investigation of the chemistry of phenylsulphonylcyclopentadiene 1983 ·Journal of the Chemical Society Perkin Transactions 1 ·Alexander J. Bridges,John W. Fischer	6
20	Phenylthiocopper trimethylphosphite complex. A reagent for the preparation of thioallenes. 1980 ·Tetrahedron Letters ·Alexander J. Bridges	9

About Alexander J. Bridges

Alexander J. Bridges is a scholar working on Organic Chemistry, Physiology and Oncology, having authored 62 papers that have together received 7.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Quinazolinone synthesis and applications (11 papers) and Synthesis and Characterization of Heterocyclic Compounds (9 papers). The work is most often cited by research in Oncology (2.1k citations), Organic Chemistry (2.0k citations) and Molecular Biology (4.2k citations). Alexander J. Bridges has collaborated with scholars based in United States, New Zealand and Japan. Frequent co-authors include Alan R. Saltiel, David T. Dudley, Stuart J. Decker, Long Pang, David W. Fry, Wilbur R. Leopold, Amy McMichael, James M. Nelson, Alan J. Kraker and Gordon W. Rewcastle. Their work appears in journals such as Science, Chemical Reviews and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact